Table 2.
Two-stage treatment of infected THA
| Study | Year | Device | Number of hips undergoing first stage | Number of hips undergoing reimplantation | Interval to reimplantation (months) | Mean followup (months) | 90-day mortality rate | Overall mortality rate | Number of infections controlled after reimplantation/number undergoing first stage | Number of infections controlled after reimplantation/number reimplanted |
|---|---|---|---|---|---|---|---|---|---|---|
| McDonald et al. [21] | 1989 | No spacer | 82 | 82 | 18 | 65 | NR | 13/82 (16%) | 71/82 (87%) | 71/82 (87%) |
| Nestor et al. [22] | 1994 | No spacer | 34 | 34 | 8 | 47 | NR | NR | 28/34 (82%) | 28/34 (82%) |
| Lieberman et al. [18] | 1994 | No spacer | 49 | 34 | 2 | 40 | 1/49 (2%) | 5/49 (8%) | 29/46 (63%) | 29/32 (91%) |
| Tsukayama et al. [31] | 1996 | Beads | 34 | 34 | 3.7 | 46 | 0/34 (0%) | 0/34 (0%) | 29/34 (85%) | 29/34 (85%) |
| Younger et al. [36] | 1997 | Articulating | 61 | 56 | 3 | 43 | NR | 4/61 (6.6%) | 52/61 (89%) | 52/56 (93%) |
| Wang and Chen [32] | 1997 | Beads (13), no spacer (9) | 22 | 22 | 6.6 | 48 | NR | NR | 20/22 (87%) | 20/22 (87%) |
| Fehring et al. [5] | 1999 | Beads (19), no spacer (6) | 25 | 25 | 4.8 | 41 | NR | NR | 23/25 (88%) | 23/25 (88%) |
| Magnan et al. [20] | 2001 | Articulating | 10 | 8 | 5 | 35 | NR | NR | 8/10 (80%) | 8/8 (80%) |
| Koo et al. [13] | 2001 | Articulating | 24 | 22 | 1.5 | 41 | NR | 2/24 (8%) | 21/22 (95%) | 21/22 (95%) |
| Yamamoto et al. [35] | 2003 | Articulating | 17 | 15 | 4.3 | 38 | 0/17 (0%) | 0/17 (0%) | 15/17 (88%) | 15/17 (88%) |
| Evans [4] | 2004 | Articulating | 23 | 23 | 2.8 | > 24 | NR | NR | 22/23 (96%) | 22/23 (96%) |
| Buttaro et al. [1] | 2005 | No spacers | 30 | 30 | 3.5 | 32 | 0/30 (0%) | 0/30 (0%) | 29/30 (97%) | 29/30 (97%) |
| Hofmann et al. [9] | 2005 | Articulating | 42 | 35 | 3 | 76 | NR | 8/42 (19%) | 26/42 (62%) | 26/27 (96%) |
| Nusem and Morgan [23] | 2006 | Articulating (17), beads (1) | 18 | 18 | 5 | 108 | 0/18 (0%) | 5.6% (1/18) | 17/18 (94%) | 17/18 (94%) |
| Scharfenberger et al. [27] | 2007 | Articulating (28) | 28 | 8 | NR | > 24 | NR | 1/28 (3.6%) | 8/28 (29%) | 8/8 (100%) |
| Cabrita et al. [2] | 2007 | Articulating (38), no spacer (30) | 68 | 56 | NR | 48 | NR | 5/68 (7%) | 51/68 (75%) | 51/56 (91%) |
| Stockley et al. [28] | 2008 | Beads | 114 | 114 | 6.4 | 74 | NR | Not stated | 100/114 (88%) | 100/114 (88%) |
| Whittaker et al. [33] | 2009 | Articulating | 44 | 44 | 5 | 49 | NR | 3/44 (7%) | 41/44 (93%) | 41/44 (93%) |
| Lim et al. [19] | 2009 | Articulating (31), beads (6) | 45 | 42 | 4.5 | 54 | NR | 1/45 (2.2%) | 38/45 (84%) | 35/42 (83%) |
| Incavo et al. [10] | 2009 | Articulating | 11 | 11 | > 1.5 | NR | NR | NR | 9/11 (82%) | 9/11 (82%) |
| Sanchez-Sotelo et al. [26] | 2009 | Spacer (31), no spacer (138) | 169 | 169 | 9.4 | 84 | NR | 4/169 (2.4%) | 157/169 (93%) | 157/169 (93%) |
| Cordero-Ampuero et al. [3] | 2009 | No spacer | 36 | 20 | 9.1 | 53 | NR | 4/36 (11%) | 20/36 (55%) | 20/20 (100%) |
| Toulson et al. [30] | 2009 | Spacer (56), no spacer (28) | 130 | 110 | 3.4 | 64.8 | NR | 34/130 (26%) | 80/130 (68%) | 80/84 (95%) |
| Fink et al. [6] | 2009 | Articulating | 40 | 40 | NR | 35 | NR | 1/40 (2.5%) | 40/40 (100%) | 40/40 (100%) |
| Takigami et al. [29] | 2010 | HA blocks | 8 | 8 | 4 | 49 | 0/8 (0%) | NR | 8/8 (100%) | 8/8 (100%) |
| Romano et al. [25] | 2010 | Articulating | 102 | 102 | ~2.7 | 48 | NR | 3/102 (2.0%) | 98/102 (96%) | 98/102 (96%) |
| Lee et al. [16] | 2011 | Articulating | 27 | 27 | 5.5 | 98 | 0% | 2/27 (7.5%) | 26/27 (96%) | 26/27 (96%) |
| Leung et al. [17] | 2011 | Articulating | 50 | 47 | 6 | 58 | NR | 12/50 (24%) | 30/50 (60%) | 30/38 (79%) |
| Current study | 2012 | Static spacer (62); articulating (143) | 205 | 189 | ? | 53 | 8/202 (3.9%) | 91/202 (45%) | 157/202 (77%) | 157/189 (83%) |
HA = hyaluronate; NR = not reported.